ARMGO Pharma is a startup based in the Netherlands, most recent round Series B, 1 tracked investor.
Based in the Netherlands, ARMGO Pharma is a startup. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
ARMGO Pharma is a venture-backed biotech company developing Rycals, novel small-molecule drugs that target ryanodine receptor (RyR) calcium ion channels. Its lead program, ARM210, is being developed for RyR1-related myopathies and for catecholaminergic polymorphic ventricular tachycardia (CPVT).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.